Nuvation Bio Inc.(NUVB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,217 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in NUVB
Events flagged as statistical outliers against NUVB's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
NUVB quality score dropped 17 points (30→12) on a new filing
View source filing →
NUVB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Nuvation Bio Inc. (NUVB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NUVB at 37.9/100 on a 32-signal composite quality model, placing it at rank #2,217 of 2,961 stocks — the bottom half of the AI-ranked universe. NUVB scores in the top quartile across institutional flow (99.7), revenue growth (99.3). Areas of concern include free cash flow (7.6) and profitability (8.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Nuvation Bio Inc. reports quarterly revenue of $31.7M, net income of $-62.8M. Top institutional holders of NUVB by reported 13-F value include FMR, BlackRock, Decheng Capital, based on the most recent SEC filings. NUVB trades on the NYSE exchange and files with the SEC under CIK 1811063. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvation Bio Inc. directly from SEC EDGAR. Nuvation Bio Inc.'s 13F Pro composite quality score has ranged between 7 and 38 since 2025, currently 37.9 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$31.7M
Net Income
Q2 2026
$-62.8M
ROIC
Q2 2026
-40.6%
D/E Ratio
Q2 2026
0.98
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+699.0% YoYNet Income
+64.0% YoYOperating Income
+64.0% YoYEPS (Diluted)
+71.6% YoYTotal Assets
+10.0% YoYTotal Debt
+742.5% YoYOp. Cash Flow
-33.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.9M +699.0% | $7.9M | $0.00 | — | — | — |
| Net Income | $-204.6M +64.0% | $-567.9M -649.2% | $-75.8M +27.3% | $-104.2M -20.0% | $-86.8M -108.5% | $-41.7M |
| Operating Income | $-213.1M +64.0% | $-592.6M -493.7% | $-99.8M +16.6% | $-119.7M -28.3% | $-93.3M -114.3% | $-43.6M |
| EPS (Diluted) | $-0.60 +71.6% | $-2.11 -502.9% | $-0.35 +27.1% | $-0.48 -9.1% | $-0.44 | — |
| Total Assets | $594.8M +10.0% | $540.6M -13.0% | $621.5M -7.5% | $672.1M -13.4% | $776.2M +435.3% | $145.0M |
| Total Debt | $52.9M +742.5% | $6.3M | $0.00 | — | — | — |
| Operating Cash Flow | $-173.4M -33.0% | $-130.4M -91.8% | $-68.0M +29.2% | $-96.1M -40.9% | $-68.2M -86.7% | $-36.5M |
Get alerted when NUVB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nuvation Bio Inc. including:
Top Institutional Holders of NUVB
FMR LLC
$296.7M52,230,295 shBlackRock, Inc.
$156.9M27,630,837 shDecheng Capital LLC
$147.4M25,954,439 shVANGUARD CAPITAL MANAGEMENT LLC
$67.7M11,919,514 shLINDEN ADVISORS LP
$54.9M52,584,000 shOmega Fund Management, LLC
$45.9M8,081,089 shLaurion Capital Management LP
$44.4M7,820,013 shSTATE STREET CORP
$41.9M7,370,794 shUBS Group AG
$36.2M6,374,705 shGEODE CAPITAL MANAGEMENT, LLC
$35.5M6,244,805 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $296.7M | 52,230,295 |
| BlackRock, Inc. | $156.9M | 27,630,837 |
| Decheng Capital LLC | $147.4M | 25,954,439 |
| VANGUARD CAPITAL MANAGEMENT LLC | $67.7M | 11,919,514 |
| LINDEN ADVISORS LP | $54.9M | 52,584,000 |
| Omega Fund Management, LLC | $45.9M | 8,081,089 |
| Laurion Capital Management LP | $44.4M | 7,820,013 |
| STATE STREET CORP | $41.9M | 7,370,794 |
| UBS Group AG | $36.2M | 6,374,705 |
| GEODE CAPITAL MANAGEMENT, LLC | $35.5M | 6,244,805 |
Companies Similar to NUVB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Tonix Pharmaceuticals Holding Corp.
Altimmune, Inc.
4D Molecular Therapeutics, Inc.
Axsome Therapeutics, Inc.
Heartflow, Inc.
Verastem, Inc.
TScan Therapeutics, Inc.
ANAPTYSBIO, INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NUVB on your watchlist
Track score changes the day Nuvation Bio Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NUVB a good stock to buy?
13F Pro's AI-powered analysis of Nuvation Bio Inc. (NUVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUVB are available on the NUVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NUVB is classified as a mid company.
Which hedge funds own NUVB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nuvation Bio Inc.'s investment landscape.